Clinical Trial Update: Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme [Phase 3]

View source ↗

Summary

A Phase 3 study comparing IV edotecarin against temozolomide or nitrosoureas (carmustine or lomustine) in glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• BiCNU (carmustine)
• Edotecarin (edotecarin)
• Gleostine (lomustine)
• Temodar (Temozolomide)

Snippet

Sponsor: Pfizer | Conditions: Glioblastoma | Phase 3 | Status: COMPLETED